title: Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study.
abstract: Ischemic brain and peripheral white blood cells release cytokines, chemokines and other molecules that activate the peripheral white blood cells after stroke. To assess gene expression in these peripheral white blood cells, whole blood was examined using oligonucleotide microarrays in 15 patients at 2.4+/-0.5, 5 and 24 h after onset of ischemic stroke and compared with control blood samples. The 2.4-h blood samples were drawn before patients were treated either with tissue-type plasminogen activator (tPA) alone or with tPA plus Eptifibatide (the Combination approach to Lysis utilizing Eptifibatide And Recombinant tPA trial). Most genes induced in whole blood at 2 to 3 h were also induced at 5 and 24 h. Separate studies showed that the genes induced at 2 to 24 h after stroke were expressed mainly by polymorphonuclear leukocytes and to a lesser degree by monocytes. These genes included: matrix metalloproteinase 9; S100 calcium-binding proteins P, A12 and A9; coagulation factor V; arginase I; carbonic anhydrase IV; lymphocyte antigen 96 (cluster of differentiation (CD)96); monocarboxylic acid transporter (6); ets-2 (erythroblastosis virus E26 oncogene homolog 2); homeobox gene Hox 1.11; cytoskeleton-associated protein 4; N-formylpeptide receptor; ribonuclease-2; N-acetylneuraminate pyruvate lyase; BCL6; glycogen phosphorylase. The fold change of these genes varied from 1.6 to 6.8 and these 18 genes correctly classified 10/15 patients at 2.4 h, 13/15 patients at 5 h and 15/15 patients at 24 h after stroke. These data provide insights into the inflammatory responses after stroke in humans, and should be helpful in diagnosis, understanding etiology and pathogenesis, and guiding acute treatment and development of new treatments for stroke.
authors.affiliation: MIND Institute and Department of Neurology, University of California at Davis, Sacramento, California 95817, USA.
authors.forename: Yang
authors.initials: Y
authors.lastname: Tang
authors.forename: Huichun
authors.initials: H
authors.lastname: Xu
authors.forename: XinLi
authors.initials: X
authors.lastname: Du
authors.forename: Lisa
authors.initials: L
authors.lastname: Lit
authors.forename: Wynn
authors.initials: W
authors.lastname: Walker
authors.forename: Aigang
authors.initials: A
authors.lastname: Lu
authors.forename: Ruiqiong
authors.initials: R
authors.lastname: Ran
authors.forename: Jeffrey P
authors.initials: JP
authors.lastname: Gregg
authors.forename: Melinda
authors.initials: M
authors.lastname: Reilly
authors.forename: Art
authors.initials: A
authors.lastname: Pancioli
authors.forename: Jane C
authors.initials: JC
authors.lastname: Khoury
authors.forename: Laura R
authors.initials: LR
authors.lastname: Sauerbeck
authors.forename: Janice A
authors.initials: JA
authors.lastname: Carrozzella
authors.forename: Judith
authors.initials: J
authors.lastname: Spilker
authors.forename: Joseph
authors.initials: J
authors.lastname: Clark
authors.forename: Kenneth R
authors.initials: KR
authors.lastname: Wagner
authors.forename: Edward C
authors.initials: EC
authors.lastname: Jauch
authors.forename: Dongwoo J
authors.initials: DJ
authors.lastname: Chang
authors.forename: Piero
authors.initials: P
authors.lastname: Verro
authors.forename: Joseph P
authors.initials: JP
authors.lastname: Broderick
authors.forename: Frank R
authors.initials: FR
authors.lastname: Sharp
mesh_terms: D000328:Adult; D000368:Aged; D002545:Brain Ischemia / Q000097:blood* / Q000188:drug therapy; D004359:Drug Therapy, Combination; D000077542:Eptifibatide; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007249:Inflammation / Q000097:blood; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000378:metabolism*; D009504:Neutrophils / Q000378:metabolism*; D020411:Oligonucleotide Array Sequence Analysis; D010455:Peptides / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D020521:Stroke / Q000097:blood* / Q000188:drug therapy; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
chemical_list: D005343:Fibrinolytic Agents; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D010959:Tissue Plasminogen Activator; D000077542:Eptifibatide